Johannes Wohlrab1,2, David Stintzing2, Luise Schultz3, Konstantin Jügelt3, Olaf H-U Schroeder3. 1. Department of Dermatology and Venereology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. 2. Institute of Applied Dermatopharmacy, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. 3. NeuroProof GmbH, Rostock, Germany.
Abstract
BACKGROUND: Itching is considered to be a subjective symptom of the activation of neurosensory structures by different signal molecules and trigger factors. The signaling cascades responsible for it are closely linked to inflammatory processes. This explains why itching also occurs in many inflammatory diseases. One of these signaling cascades is mediated by Janus kinases (JAKs). Recently, it could be shown on a molecular level that Janus kinase 1 (JAK1) directly activates frontal cortex neurons and thus can cause chronic itching. OBJECTIVES: This study deals with the influence of different JAK inhibitors (JAKi) on the activity of chip-based neural networks of cultured frontal cortex neurons by investigating neurophysiological activity parameters. This in vitro model provides information on dose-dependent effects of model substances with different specificity regarding the inhibition of different JAKs. METHODS: Tofacitinib (pan-JAKi), baricitinib (JAK1/2i), and upadacitinib (JAK1i) in a concentration range from 10 nmol/L to 50 μmol/L were tested in a microelectrode array neurochip culture system. RESULTS: The results show that the inhibition of the neuronal activity of frontal cortex neurons increases with JAK1 selectivity and is dependent on concentration. CONCLUSION: These observations are supported by data from clinical studies in atopic dermatitis and psoriasis. The clinical relevance of these results must be proven by further clinical studies with subjective and objective parameters for itching.
BACKGROUND: Itching is considered to be a subjective symptom of the activation of neurosensory structures by different signal molecules and trigger factors. The signaling cascades responsible for it are closely linked to inflammatory processes. This explains why itching also occurs in many inflammatory diseases. One of these signaling cascades is mediated by Janus kinases (JAKs). Recently, it could be shown on a molecular level that Janus kinase 1 (JAK1) directly activates frontal cortex neurons and thus can cause chronic itching. OBJECTIVES: This study deals with the influence of different JAK inhibitors (JAKi) on the activity of chip-based neural networks of cultured frontal cortex neurons by investigating neurophysiological activity parameters. This in vitro model provides information on dose-dependent effects of model substances with different specificity regarding the inhibition of different JAKs. METHODS: Tofacitinib (pan-JAKi), baricitinib (JAK1/2i), and upadacitinib (JAK1i) in a concentration range from 10 nmol/L to 50 μmol/L were tested in a microelectrode array neurochip culture system. RESULTS: The results show that the inhibition of the neuronal activity of frontal cortex neurons increases with JAK1 selectivity and is dependent on concentration. CONCLUSION: These observations are supported by data from clinical studies in atopic dermatitis and psoriasis. The clinical relevance of these results must be proven by further clinical studies with subjective and objective parameters for itching.
Authors: Sonja Ständer; Thomas Luger; Joseph C Cappelleri; Andrew G Bushmakin; Carla Mamolo; Michael A Zielinski; Anna M Tallman; Gil Yosipovitch Journal: Acta Derm Venereol Date: 2018-03-13 Impact factor: 4.437
Authors: John J O'Shea; Daniella M Schwartz; Alejandro V Villarino; Massimo Gadina; Iain B McInnes; Arian Laurence Journal: Annu Rev Med Date: 2015 Impact factor: 13.739
Authors: Iain B McInnes; Nicole L Byers; Richard E Higgs; Jonathan Lee; William L Macias; Songqing Na; Robert A Ortmann; Guilherme Rocha; Terence P Rooney; Thomas Wehrman; Xin Zhang; Steven H Zuckerman; Peter C Taylor Journal: Arthritis Res Ther Date: 2019-08-02 Impact factor: 5.156